Preclinical pharmacokinetics of 4-hydroxy isoleucine using LC–MS/MS: a potential polycystic ovary syndrome phytopharmaceutical therapeutics: supplementary tables

Aim: To study the preclinical pharmacokinetics of 4-hydroxy isoleucine (4-HIL) targeted for polycystic

ovary syndrome. Methodology: The quantitative bioanalysis of 4-HIL in different biological matrices

in female Sprage-Dawley rats using LC–MS/MS. Results: At 50 mg/kg, 4-HIL had 56.8% absolute

oral bioavailability. It was quickly absorbed and distributed in various tissues in order of small

intestine > kidney > ovary > spleen > lung > liver > heart > brain after oral administration. Moreover,

11.07% of 4-HIL was recovered in urine and feces within 72 h. Conclusion: 4-HIL levels in vital organs were

found safe, as per tissue distribution results. Hence, 4-HIL could be used as promising therapeutics for

management of polycystic ovary syndrome.